Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pancrecarb MS-16 in Cystic Fibrosis
NCT00432861Phase 3Completed
- Start
- Jan 2007
- Primary completion
- Sep 2007
- Modality
- Replacement Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in exocrine pancreatic insufficiency (EPI) and cystic fibrosis (CF) comparing Pancrecarb MS-16 with Placebo (2 arms). Primary endpoint: Percent Coefficient of Fat Absorption at 72 hours. Started Jan 2007; status: completed.
02
Drugs
Pancrecarb
03
Conditions
exocrine pancreatic insufficiency (EPI)cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT00432861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00432861.